2. Academic Validation
  3. Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ

Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ

  • J Med Chem. 2016 Mar 10;59(5):1830-9. doi: 10.1021/acs.jmedchem.5b01311.
Florentine U Rutaganira 1,  Melissa L Fowler 2,  Jacob A McPhail 2,  Michael A Gelman 3,  Khanh Nguyen 3,  Anming Xiong 3,  Gillian L Dornan 2,  Brandon Tavshanjian 1,  Jeffrey S Glenn 3 4,  Kevan M Shokat 1,  John E Burke 2
Affiliations

Affiliations

  • 1 Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco (UCSF) , San Francisco, California 94143, United States.
  • 2 Department of Biochemistry and Microbiology, University of Victoria , Victoria, BC V8W 2Y2, Canada.
  • 3 Department of Medicine and Department of Microbiology & Immunology, Stanford University , Palo Alto, California 94305, United States.
  • 4 Veterans Administration Medical Center , Palo Alto, California 94304, United States.
PMID: 26885694 DOI: 10.1021/acs.jmedchem.5b01311
Abstract

Type III phosphatidylinositol 4-kinase (PI4KIIIβ) is an essential Enzyme in mediating membrane trafficking and is implicated in a variety of pathogenic processes. It is a key host factor mediating replication of RNA viruses. The design of potent and specific inhibitors of this Enzyme will be essential to define its cellular roles and may lead to novel Antiviral therapeutics. We previously reported the PI4K Inhibitor PIK93, and this compound has defined key functions of PI4KIIIβ. However, this compound showed high cross reactivity with class I and III PI3Ks. Using structure-based drug design, we have designed novel potent and selective (>1000-fold over class I and class III PI3Ks) PI4KIIIβ inhibitors. These compounds showed Antiviral activity against hepatitis C virus. The co-crystal structure of PI4KIIIβ bound to one of the most potent compounds reveals the molecular basis of specificity. This work will be vital in the design of novel PI4KIIIβ inhibitors, which may play significant roles as Antiviral therapeutics.

Figures
Products